Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) shares shot up 8.5% on Tuesday . The company traded as high as $13.11 and last traded at $13.31. 230,143 shares were traded during mid-day trading, a decline of 76% from the average session volume of 966,247 shares. The stock had previously closed at $12.27.
Wall Street Analysts Forecast Growth
Several research firms recently commented on IART. JMP Securities dropped their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Truist Financial cut their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Wells Fargo & Company dropped their target price on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Finally, JPMorgan Chase & Co. dropped their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Four analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $18.63.
Read Our Latest Report on Integra LifeSciences
Integra LifeSciences Trading Up 7.6%
The company has a 50 day simple moving average of $13.41 and a 200 day simple moving average of $19.23. The stock has a market capitalization of $1.03 billion, a PE ratio of -34.71, a P/E/G ratio of 0.69 and a beta of 1.17. The company has a current ratio of 1.21, a quick ratio of 0.72 and a debt-to-equity ratio of 0.81.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The company had revenue of $382.65 million for the quarter, compared to analysts' expectations of $381.17 million. During the same quarter last year, the company earned $0.55 EPS. Integra LifeSciences's revenue for the quarter was up 3.7% compared to the same quarter last year. Analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in IART. Assenagon Asset Management S.A. boosted its holdings in Integra LifeSciences by 2,418.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock valued at $39,581,000 after purchasing an additional 1,728,480 shares in the last quarter. Soleus Capital Management L.P. purchased a new stake in shares of Integra LifeSciences in the fourth quarter valued at approximately $28,940,000. Paradigm Capital Management Inc. NY boosted its stake in shares of Integra LifeSciences by 170.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock valued at $32,457,000 after buying an additional 901,600 shares in the last quarter. Lord Abbett & CO. LLC grew its holdings in Integra LifeSciences by 86.8% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company's stock worth $30,210,000 after acquiring an additional 618,773 shares during the period. Finally, Norges Bank purchased a new position in Integra LifeSciences in the fourth quarter worth $8,967,000. 84.78% of the stock is owned by hedge funds and other institutional investors.
Integra LifeSciences Company Profile
(
Get Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
